MARKET

IRD

IRD

Opus Genetics
NASDAQ
3.010
+0.430
+16.67%
After Hours: 3.005 -0.005 -0.15% 19:55 02/06 EST
OPEN
2.640
PREV CLOSE
2.580
HIGH
3.080
LOW
2.640
VOLUME
2.88M
TURNOVER
--
52 WEEK HIGH
3.080
52 WEEK LOW
0.6500
MARKET CAP
207.58M
P/E (TTM)
-1.7070
1D
5D
1M
3M
1Y
5Y
1D
Opus Genetics: Favorable Risk‑Reward in OPGx-BEST1 Gene Therapy Underpins Buy Rating and $6 Price Target
TipRanks · 2d ago
Analysts Are Bullish on These Healthcare Stocks: Adaptive Biotechnologies (ADPT), Opus Genetics (IRD)
TipRanks · 2d ago
Opus Genetics to Present Preliminary Results of OPGx-BEST1 Gene Therapy at Macula Society Annual Meeting
Reuters · 6d ago
Weekly Report: what happened at IRD last week (0126-0130)?
Weekly Report · 6d ago
Where Opus Genetics Stands With Analysts
Benzinga · 01/28 12:00
Opus Genetics: Validated AAV Platform and High-Value IRD Pipeline Underpin Buy Rating and Attractive Risk‑Reward
TipRanks · 01/28 11:45
Opus Genetics Price Target Maintained With a $7.00/Share by BTIG
Dow Jones · 01/28 10:17
BTIG Reiterates Buy on Opus Genetics, Maintains $7 Price Target
Benzinga · 01/28 10:08
More
About IRD
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.

Webull offers Opus Genetics Inc stock information, including NASDAQ: IRD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRD stock methods without spending real money on the virtual paper trading platform.